Cornerstone Wealth Management LLC Takes Position in ResMed Inc. (RMD)  Stephan Jacobs | Aug 17th, 2018
Cornerstone Wealth Management LLC acquired a new stake in ResMed Inc. (NYSE:RMD) during the second quarter, HoldingsChannel reports. The institutional investor acquired 17,331 shares of the medical equipment provider's stock, valued at approximately $167,000.
Several other hedge funds have also recently made changes to their positions in the company. Hudson Valley Investment Advisors Inc. ADV grew its holdings in ResMed by 2.2% during the second quarter. Hudson Valley Investment Advisors Inc. ADV now owns 60,974 shares of the medical equipment provider's stock worth $6,316,000 after acquiring an additional 1,301 shares during the period. Dupont Capital Management Corp acquired a new stake in ResMed during the first quarter worth about $121,000. Norinchukin Bank The grew its holdings in ResMed by 18.3% during the first quarter. Norinchukin Bank The now owns 14,117 shares of the medical equipment provider's stock worth $1,390,000 after acquiring an additional 2,182 shares during the period. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp grew its holdings in ResMed by 19.3% during the first quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp now owns 87,733 shares of the medical equipment provider's stock worth $8,639,000 after acquiring an additional 14,209 shares during the period. Finally, Mackay Shields LLC acquired a new stake in ResMed during the first quarter worth about $2,371,000. 62.68% of the stock is currently owned by institutional investors and hedge funds. Get ResMed alerts:
Several research firms recently commented on RMD. Zacks Investment Research raised ResMed from a "sell" rating to a "hold" rating in a report on Tuesday, July 31st. UBS Group lowered ResMed from a "buy" rating to a "neutral" rating in a report on Tuesday, April 24th. Finally, Goldman Sachs Group began coverage on ResMed in a report on Sunday, July 1st. They set a "buy" rating on the stock. Three investment analysts have rated the stock with a sell rating, six have issued a hold rating and four have assigned a buy rating to the company. ResMed presently has an average rating of "Hold" and an average target price of $77.33.
Shares of RMD stock opened at $106.84 on Friday. The company has a market cap of $15.38 billion, a price-to-earnings ratio of 30.27, a price-to-earnings-growth ratio of 2.78 and a beta of 0.89. The company has a current ratio of 2.08, a quick ratio of 1.56 and a debt-to-equity ratio of 0.13. ResMed Inc. has a 12-month low of $72.49 and a 12-month high of $109.97.
ResMed (NYSE:RMD) last issued its quarterly earnings results on Thursday, August 2nd. The medical equipment provider reported $0.95 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.95. The company had revenue of $623.63 million for the quarter, compared to the consensus estimate of $622.78 million. ResMed had a return on equity of 24.74% and a net margin of 13.49%. ResMed's revenue for the quarter was up 12.0% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.77 earnings per share. research analysts predict that ResMed Inc. will post 3.66 EPS for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Thursday, September 20th. Shareholders of record on Thursday, August 16th will be given a dividend of $0.37 per share. The ex-dividend date of this dividend is Wednesday, August 15th. This represents a $1.48 dividend on an annualized basis and a yield of 1.39%. This is an increase from ResMed's previous quarterly dividend of $0.35. ResMed's dividend payout ratio is currently 39.66%.
In other ResMed news, CFO Brett Sandercock sold 2,000 shares of the stock in a transaction that occurred on Wednesday, August 15th. The stock was sold at an average price of $107.45, for a total transaction of $214,900.00. The sale was disclosed in a filing with the SEC, which is accessible through this link . Also, Director Richard Sulpizio sold 28,403 shares of the stock in a transaction that occurred on Wednesday, May 30th. The stock was sold at an average price of $102.78, for a total value of $2,919,260.34. Following the transaction, the director now owns 35,823 shares in the company, valued at approximately $3,681,887.94. The disclosure for this sale can be found here . Insiders have sold 41,823 shares of company stock worth $4,342,578 in the last quarter. 1.77% of the stock is currently owned by company insiders.
About ResMed
ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep disordered breathing, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes.
Read More: Understanding Relative Strength Index
Want to see what other hedge funds are holding RMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ResMed Inc. (NYSE:RMD). Receive News & Ratings for ResMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed and related companies with MarketBeat.com's FREE daily email newsletter . Ã‚